Identification of substituted 3-[(4,5,6,7-tetrahydro-1H- indol-2-yl)methylene]-1,3-dihydroindol-2-ones as growth factor receptor inhibitors for VEGF-R2 (Flk-1/KDR), FGF-R1, and PDGF-Rβ tyrosine kinases

Journal of Medicinal Chemistry

Volumn 43, Issue 14, 2000, Pages 2655-2663

  Sun, Li ^a   Tran, Ngoc ^a   Liang, Congxing ^a   Hubbard, Steve ^b   Tang, Flora ^a   Lipson, Kenneth ^a   Schreck, Randall ^a   Zhou, Yong ^a   McMahon, Gerald ^a   Tang, Cho ^a  

^a SUGEN INC   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 3 [(4,5 DIMETHYL 1H PYRROL 2 YL)METHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; 3 [(4,5,6,7 TETRAHYDRO 1H INDOL 2 YL)METHYLENE] 1,3 DIHYDROINDOL 2 ONE DERIVATIVE; 3 [2 (2 OXO 1,2 DIHYDROINDOL 3 YLIDENEMETHYL) 4,5,6,7 TETRAHYDRO 1H INDOL 3 YL]PROPIONIC ACID; 3 [2 (5 BROMO 2 OXO 1,2 DIHYDROINDOL 3 YLIDENEMETHYL) 4,5,6,7 TETRAHYDRO 1H INDOL 3 YL]PROPIONIC ACID; FIBROBLAST GROWTH FACTOR RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; CANCER; CELL PROLIFERATION; CONTROLLED STUDY; DRUG DESIGN; DRUG INHIBITION; DRUG POTENCY; DRUG STRUCTURE; MOUSE; NONHUMAN; PHARMACOPHORE; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIVISION; CELL LINE; CRYSTALLOGRAPHY, X-RAY; ENZYME INHIBITORS; HUMANS; INDOLES; INHIBITORY CONCENTRATION 50; MICE; MODELS, MOLECULAR; PHOSPHORYLATION; PROPIONIC ACIDS; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; RECEPTORS, GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; STRUCTURE-ACTIVITY RELATIONSHIP; TYROSINE; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 0034644272     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9906116     Document Type: Article

References (17)

1. Folkman, J. What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst. 1990, 82, 4-6.
2. Folkman, J.; Shing, Y. Angiogenesis. J. Biol. Chem. 1992, 267, 10931-10934.
3. Strawn, L. M; McMahon, G.; App, H.; Schreck, R.; Kuchler, W. R.; Longhi, M. P.; Hui, T. H., Tang, C.; Levitzki, A., Gazit, A.; Chen, I.; Keri, G.; Orfi, L.; Risau, W.; Flamme, I.; Ullrich, A.; Hirth, K. P.; Shawver, L. K. Flk-1 as a target for tumor growth inhibition. Cancer Res. 1996, 56, 3540-3545.
4. Shawver, L. K.; Lipson, K. E.; Fong, T. A. T.; McMahon, G.; Plowman, G. D.; Strawn, L. M. Receptor tyrosine kinases as targets for inhibition of angiogenesis. Drug Discovery Today 1997, 2 (2), 50-63.
5. Pepper, M. S.; Ferrara, N.; Orci, L.; Montessano, R. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem. Biophys. Res. Commun. 1992, 189, 824-831.
6. Hanahan, D.; Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86, 353-364.
7. Hennequin, L. F.; Thomas, A. P.; Johnstone, C.; Ple, P.; Stokes, E. S. E.; Ogilvie, D. J.; Dukes, M.; Wedge, S. R. 90th Annual Meeting of American Association for Cancer Research, Philadelphia, PA, Apr 10-14, 1999; Abstract 457.
8. Sun, L.; Tran, N.; Tang, T.; App, H.; Hirth, P.; McMahon, G.; Tang, C. Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity towards particular receptor tyrosine kinases. J. Med. Chem. 1998, 41 (14), 2588-2603.
9. Sun, L.; Tran, N.; Liang, C.; Tang, F.; Rice, A.; Schreck, R.; Waltz, K.; Shawver, L. K.; McMahon, G.; Tang, C. Design, synthesis, and evaluations of substituted 3-[(3-or 4-carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases. J. Med. Chem. 1999, 42 (25), 5120-5130.
10. Fong, A. T. T.; Shawver, L. K.; Sun, L.; Tang, C.; App. H.; Powell, T. J.; Kim, Y. H.; Schreck, R.; Wang, X. Y.; Risau, W.; Ullrich, A.; Hirth, K. P.; McMahon, G. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. 1999, 59, 99-106.
11. Laird, A. D.; Vajkoczy, P.; Shawver, L. K.; Thurnher, A.; Liang, C.; Mohammadi, M.; Schlessinger, J.; Ullrich, A.; Hubbard, S. R.; Blake, R. A.; Fong, T. A. T.; Strawn, L. M.; Sun, L.; Tang, C.; Hawtin, R.; Tang, F.; Shenoy, N.; Hirth, K. P.; McMahon, G.; Cherrington, J. M. SU6668 is a potent anti-angiogenic and antitumor agent which induces regression of established tumors. Cancer Res., in press.
12. Mohammadi, M.; McMahon, G., Sun, L.; Tang, P. C.; Hirth, P.; Yeh, B. K.; Hubbard, S. R.; Schlessinger, J. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science 1997, 276, 955-960.
13. Abram, C. L.; Courtneidge, S. A. Src family tyrosine kinases and growth factor signaling. In preparation.
14. Mohammadi, M.; Schlessinger, J.; Hubbard, S. R. Structure of the FGF receptor tyrosine kinase domain reveals a novel autoinhibitory mechanism. Cell 1996, 86, 577-587.
15. Otwinowski, Z.; Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 1997, 276, 307-326.
16. Brunger, A. T.; et al. Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr. D 1998, 54, 905-921.
17. Jones, T. A.; Zou, J. Y.; Cowan, S. W.; Kjeldgaard, M. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr. A 1991, 47, 110-119.